Abstract
"The Australian Government should review its position and support intellectual property waivers in the pandemic accord"
Throughout the coronavirus disease 2019 (COVID-19) pandemic, inequities in access to COVID-19 vaccines, diagnostics and therapeutics have been vast and persistent. By the end of 2022, only 26% of people in low income countries had received a COVID-19 vaccine dose. Less than one in 50 of the three billion diagnostic tests administered globally by March 2022 were performed in low income countries. Further, low and middle income countries have had very little access to therapeutics, particularly antivirals such as nirmatrelvir–ritonavir (Paxlovid, Pfizer) and molnupiravir (Lagevrio, Merck Sharpe & Dohme)...
Throughout the coronavirus disease 2019 (COVID-19) pandemic, inequities in access to COVID-19 vaccines, diagnostics and therapeutics have been vast and persistent. By the end of 2022, only 26% of people in low income countries had received a COVID-19 vaccine dose. Less than one in 50 of the three billion diagnostic tests administered globally by March 2022 were performed in low income countries. Further, low and middle income countries have had very little access to therapeutics, particularly antivirals such as nirmatrelvir–ritonavir (Paxlovid, Pfizer) and molnupiravir (Lagevrio, Merck Sharpe & Dohme)...
Original language | English |
---|---|
Pages (from-to) | 46-48 |
Number of pages | 3 |
Journal | Medical Journal of Australia |
Volume | 219 |
Issue number | 2 |
Early online date | 11 Jun 2023 |
DOIs |
|
Publication status | Published - Jul 2023 |
Keywords
- COVID-19
- Global health
- Health policy
- Intellectual property
- Pharmaceuticals
- Public health
- World Health Organization